NASDAQ:CSTL Castle Biosciences (CSTL) Stock Forecast, Price & News $16.66 -0.28 (-1.65%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$16.37▼$16.7950-Day Range$15.30▼$19.9352-Week Range$9.26▼$30.08Volume101,090 shsAverage Volume399,630 shsMarket Capitalization$446.65 millionP/E RatioN/ADividend YieldN/APrice Target$32.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Castle Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside93.8% Upside$32.29 Price TargetShort InterestHealthy2.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.25Based on 4 Articles This WeekInsider TradingSelling Shares$1.37 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.68) to ($3.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector269th out of 965 stocksMedical Laboratories Industry7th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.29, Castle Biosciences has a forecasted upside of 93.8% from its current price of $16.66.Amount of Analyst CoverageCastle Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.67% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 3.59%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 3.5 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Castle Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for CSTL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,368,879.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions85.75% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($3.68) to ($3.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -4.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Castle Biosciences (NASDAQ:CSTL) StockCastle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Read More CSTL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Stock News HeadlinesSeptember 22, 2023 | baystreet.caCastle Scales Higher on Industry AwardSeptember 19, 2023 | finance.yahoo.comCastle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare IndustrySeptember 22, 2023 | Stansberry Research (Ad)Are "The Magnificent Seven" the Next Sears?The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.September 14, 2023 | finance.yahoo.comTissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s EsophagusSeptember 12, 2023 | finance.yahoo.comCastle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh LaboratorySeptember 9, 2023 | finance.yahoo.comIntegrating Drug-Drug Interactions and Lifestyle Factors with Drug-Gene Interactions Provided by Castle Biosciences’ IDgenetix® Test Significantly Impacted the Number of Drug Recommendations for Patients with Moderate to Severe DepressionSeptember 8, 2023 | finance.yahoo.comTissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s EsophagusSeptember 6, 2023 | finance.yahoo.comCastle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023September 22, 2023 | Stansberry Research (Ad)Are "The Magnificent Seven" the Next Sears?The former retail giant’s sales once accounted for 1% of the U.S. economy. Now it’s nearly extinct. Will the same happen to big tech? Learn more here.August 7, 2023 | finance.yahoo.comNew Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s EsophagusAugust 5, 2023 | fool.comCastle Biosciences (NASDAQ: CSTL)August 3, 2023 | finance.yahoo.comCastle Biosciences Reports Second Quarter 2023 ResultsAugust 3, 2023 | finance.yahoo.comHere's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 EarningsAugust 3, 2023 | finance.yahoo.comCastle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comWhy Castle Biosciences Stock Is Jumping TodayAugust 1, 2023 | benzinga.comCastle Biosciences's Earnings: A PreviewAugust 1, 2023 | finance.yahoo.comCastle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth ConferenceJuly 28, 2023 | markets.businessinsider.comBTIG Remains a Buy on Castle Biosciences (CSTL)July 19, 2023 | finance.yahoo.comCastle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2July 18, 2023 | finance.yahoo.comCastle Biosciences to Host Second Annual Castle Cares Charity WalkJuly 17, 2023 | finance.yahoo.comCastle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive YearJuly 13, 2023 | finance.yahoo.comWhy Shares of Castle Biosciences Fell This WeekJuly 12, 2023 | benzinga.comDirector of Castle Biosciences Makes $1.02M SaleJuly 11, 2023 | seekingalpha.comCastle Biosciences: Reimbursement Reversal Win Masks Profitability ProblemJuly 11, 2023 | benzinga.comBragar Eagel & Squire, P.C. Is Investigating Advance Auto Parts, EPAM, and Castle and Encourages Investors to Contact the FirmJuly 10, 2023 | markets.businessinsider.comSVB Securities Sticks to Their Buy Rating for Castle Biosciences (CSTL)July 8, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for Castle Biosciences (CSTL)See More Headlines Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Company Calendar Last Earnings8/02/2023Today9/21/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees582Year FoundedN/APrice Target and Rating Average Stock Price Forecast$32.29 High Stock Price Forecast$41.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+93.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,140,000.00 Net Margins-53.04% Pretax Margin-52.98% Return on Equity-22.57% Return on Assets-20.22% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.80 Sales & Book Value Annual Sales$137.04 million Price / Sales3.26 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book1.10Miscellaneous Outstanding Shares26,810,000Free Float24,746,000Market Cap$446.65 million OptionableNot Optionable Beta0.81 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Derek J. Maetzold (Age 61)Founder, CEO, Pres & Director Comp: $1.45MMr. Frank Stokes (Age 53)CFO & Treasurer Comp: $849.36kMs. Kristen M. Oelschlager R.N. (Age 55)RN, Chief Operating Officer Comp: $782.7kMr. Tobin W. Juvenal (Age 63)Chief Commercial Officer Comp: $782.7kCamilla ZuckeroVP of Investor Relations & Corp. AffairsMs. Alice Bahner IzzoSr. VP of MarketingMs. Keli GreenbergVP of HR & Exec. Director of HRDr. Robert W. Cook Ph.D. (Age 51)Sr. VP of R&D Mr. Bernhard E. Spiess (Age 63)Company Sec. More ExecutivesKey CompetitorsCareDxNASDAQ:CDNAProgenityNASDAQ:PROGCelcuityNASDAQ:CELCInvitaeNYSE:NVTAViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsBarclays PLCSold 2,944 shares on 9/21/2023Ownership: 0.035%Portside Wealth Group LLCBought 120,230 shares on 9/1/2023Ownership: 0.448%Derek J MaetzoldSold 718 sharesTotal: $14,395.90 ($20.05/share)Daniel BradburySold 1,802 sharesTotal: $36,112.08 ($20.04/share)Derek J MaetzoldSold 1,622 sharesTotal: $32,488.66 ($20.03/share)View All Insider TransactionsView All Institutional Transactions CSTL Stock - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price forecast for 2023? 4 analysts have issued 1-year price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $41.00. On average, they predict the company's stock price to reach $32.29 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2023? Castle Biosciences' stock was trading at $23.54 at the beginning of the year. Since then, CSTL stock has decreased by 29.2% and is now trading at $16.66. View the best growth stocks for 2023 here. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our CSTL earnings forecast. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.01) by $0.31. The company earned $50.14 million during the quarter, compared to the consensus estimate of $43.51 million. Castle Biosciences had a negative net margin of 53.04% and a negative trailing twelve-month return on equity of 22.57%. What ETF holds Castle Biosciences' stock ? First Trust Nasdaq Lux Digital Health Solutions ETF holds 98 shares of CSTL stock, representing 0.21% of its portfolio. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? (CSTL) raised $50 million in an IPO on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Castle Biosciences' stock symbol? Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL." Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (11.51%), Granahan Investment Management LLC (9.43%), BlackRock Inc. (7.95%), Principal Financial Group Inc. (5.07%), Bellevue Group AG (4.19%) and Palisade Capital Management LP (2.25%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Ellen Goldberg, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Castle Biosciences' stock price today? One share of CSTL stock can currently be purchased for approximately $16.66. How much money does Castle Biosciences make? Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $446.65 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. How many employees does Castle Biosciences have? The company employs 582 workers across the globe. How can I contact Castle Biosciences? Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com. This page (NASDAQ:CSTL) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.